Eindhoven, Netherlands — In a major step toward transforming chronic migraine care, Dutch startup Salvia BioElectronics has raised €53 million in Series B funding to advance its novel neuromodulation therapy, MySalvia Therapy — a minimally invasive implant designed to offer targeted relief to millions living with debilitating migraines.
The round was led by European DeepTech investor Innovation Industries, with support from Invest-NL, the EIC Fund, and a lineup of returning backers including Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, BOM, and Thuja Capital.
Founded in 2017, Salvia BioElectronics is tackling one of the world’s leading causes of disability with a solution that blends hardware innovation with clinical rigor. Its flagship product, MySalvia Therapy, features ultra-thin bioelectronic implants placed under the skin of the forehead and back of the head. When migraine symptoms arise, patients can use a small external device to activate nerve stimulation — a user-friendly approach that puts control directly into the hands of patients.
“Chronic migraine robs people of their work, social lives, and independence. We’re here to give that back,” said CEO and founder Hubert Martens. “This investment allows us to push forward with clinical trials, regulatory approvals, and prepare for market entry.”
The fresh capital will fuel Salvia’s clinical development, including the ongoing RECLAIM study — a double-blind, sham-controlled trial involving chronic migraine sufferers. The company is simultaneously working toward regulatory clearance in the US, Europe, and Australia, including FDA market authorisation under its Breakthrough Device designation.
For investors, the appeal lies in the scale of the problem and the simplicity of Salvia’s solution. Migraine costs the EU and US an estimated €96.6 billion annually in productivity loss and healthcare expenses. Yet current treatments often fall short, with many patients discontinuing use due to side effects or lack of effectiveness.
“MySalvia Therapy isn’t just another option — it’s a game-changer,” said Caaj Greebe, Partner at Innovation Industries. “The team’s combination of clinical insight and engineering precision makes them uniquely positioned to deliver a breakthrough for millions of patients.”
In contrast to traditional neurostimulation devices that often require invasive surgery, Salvia’s implants are designed to be slim, discreet, and easier to place — reducing surgical complexity and recovery time. The company also sees potential in expanding its technology to treat cluster headaches, another severe form of neurological pain.
With this latest funding, Salvia BioElectronics is poised to enter a critical phase — one that could mark a turning point in how chronic migraines are treated worldwide.
